Drug Facts
Composition & Profile
Identifiers & Packaging
16. HOW SUPPLIED/STORAGE AND HANDLING EMERPHED (ephedrine sulfate injection) is a clear, colorless solution available as single-dose vials containing 5 mg/mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base and is supplied as follows: NDC Presentation 14789-250-07 10 mL clear glass, single-dose vial; strength 50 mg/10 mL (5 mg/mL) 14789-250-10 10 mL vials packaged in a carton of 10 EMERPHED-PFS (ephedrine sulfate injection) is a clear, colorless solution available as single-dose pre-filled syringes containing 5 mg/mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base and is supplied as follows: NDC Presentation 14789-251-09 5 mL clear glass, single-dose pre-filled syringe; strength 25 mg/5 mL (5 mg/mL) 14789-251-10 5 mL pre-filled syringes packaged in a carton of 10 14789-252-09 10 mL clear glass, single-dose pre-filled syringe; strength 50 mg/10 mL (5 mg/mL) 14789-252-10 10 mL pre-filled syringes packaged in a carton of 10 The single-dose prefilled syringes, each fitted with a removable tip cap and plunger rods, are presented in a carton. EMERPHED (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) and EMERPHED-PFS (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) and 25 mg/5 mL (5 mg/mL) are not made with natural rubber latex. Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in carton until time of use. For single dose only. Discard unused portion. The single-dose prefilled syringe is intended for use in one patient during one surgical procedure. Patent, www.emerphed.com/patent Manufactured in Italy for: Nexus Pharmaceuticals, LLC 400 Knightsbridge Parkway Lincolnshire, IL 60069 USA EPFPI01ITR06 Logo; Principal Display Panel – 5 mg/mL Carton Label NDC 14789- 252 -10 Rx Only EMERPHED ® -PFS (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) (equivalent to 38 mg/10 mL ephedrine base) Premixed formulation -Do not dilute For Intravenous Use Only 10 x 10 mL Single-dose Prefilled Syringes NEXUS PHARMACEUTICALS Principal Display Panel – 5 mg/mL Carton Label; Principal Display Panel – 5 mg/mL Vial Label NDC 14789-252-09 Rx Only EMERPHED ® -EPF (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) (equivalent to 38 mg/5 mL ephedrine base) Premixed formulation –Do not dilute For Intravenous Use Only 10 mL Single-dose Prefilled Syringe Principal Display Panel – 5 mg/mL Vial Label; Principal Display Panel – 25 mg/5 mL Carton Label NDC 14789- 251 -10 Rx Only EMERPHED ® -EPF (ephedrine sulfate injection) 25 mg/5 mL (5 mg/mL) (equivalent to 19 mg/5 mL ephedrine base) Premixed formulation -Do not dilute For Intravenous Use Only 10 x 5 mL Single-dose Prefilled Syringes NEXUS PHARMACEUTICALS Principal Display Panel – 25 mg/5 mL Carton Label; Principal Display Panel – 25 mg/5 mL Vial Label NDC 14789-251-09 Rx Only EMERPHED ® -EPF (ephedrine sulfate injection) 25 mg/5 mL (5 mg/mL) (equivalent to 19 mg/5 mL ephedrine base) Premixed formulation –Do not dilute For Intravenous Use Only 5 mL Single-dose Prefilled Syringe Principal Display Panel – 25 mg/5 mL Vial Label
- 16. HOW SUPPLIED/STORAGE AND HANDLING EMERPHED (ephedrine sulfate injection) is a clear, colorless solution available as single-dose vials containing 5 mg/mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base and is supplied as follows: NDC Presentation 14789-250-07 10 mL clear glass, single-dose vial; strength 50 mg/10 mL (5 mg/mL) 14789-250-10 10 mL vials packaged in a carton of 10 EMERPHED-PFS (ephedrine sulfate injection) is a clear, colorless solution available as single-dose pre-filled syringes containing 5 mg/mL ephedrine sulfate, equivalent to 3.8 mg/mL ephedrine base and is supplied as follows: NDC Presentation 14789-251-09 5 mL clear glass, single-dose pre-filled syringe; strength 25 mg/5 mL (5 mg/mL) 14789-251-10 5 mL pre-filled syringes packaged in a carton of 10 14789-252-09 10 mL clear glass, single-dose pre-filled syringe; strength 50 mg/10 mL (5 mg/mL) 14789-252-10 10 mL pre-filled syringes packaged in a carton of 10 The single-dose prefilled syringes, each fitted with a removable tip cap and plunger rods, are presented in a carton. EMERPHED (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) and EMERPHED-PFS (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) and 25 mg/5 mL (5 mg/mL) are not made with natural rubber latex. Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in carton until time of use. For single dose only. Discard unused portion. The single-dose prefilled syringe is intended for use in one patient during one surgical procedure. Patent, www.emerphed.com/patent Manufactured in Italy for: Nexus Pharmaceuticals, LLC 400 Knightsbridge Parkway Lincolnshire, IL 60069 USA EPFPI01ITR06 Logo
- Principal Display Panel – 5 mg/mL Carton Label NDC 14789- 252 -10 Rx Only EMERPHED ® -PFS (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) (equivalent to 38 mg/10 mL ephedrine base) Premixed formulation -Do not dilute For Intravenous Use Only 10 x 10 mL Single-dose Prefilled Syringes NEXUS PHARMACEUTICALS Principal Display Panel – 5 mg/mL Carton Label
- Principal Display Panel – 5 mg/mL Vial Label NDC 14789-252-09 Rx Only EMERPHED ® -EPF (ephedrine sulfate injection) 50 mg/10 mL (5 mg/mL) (equivalent to 38 mg/5 mL ephedrine base) Premixed formulation –Do not dilute For Intravenous Use Only 10 mL Single-dose Prefilled Syringe Principal Display Panel – 5 mg/mL Vial Label
- Principal Display Panel – 25 mg/5 mL Carton Label NDC 14789- 251 -10 Rx Only EMERPHED ® -EPF (ephedrine sulfate injection) 25 mg/5 mL (5 mg/mL) (equivalent to 19 mg/5 mL ephedrine base) Premixed formulation -Do not dilute For Intravenous Use Only 10 x 5 mL Single-dose Prefilled Syringes NEXUS PHARMACEUTICALS Principal Display Panel – 25 mg/5 mL Carton Label
- Principal Display Panel – 25 mg/5 mL Vial Label NDC 14789-251-09 Rx Only EMERPHED ® -EPF (ephedrine sulfate injection) 25 mg/5 mL (5 mg/mL) (equivalent to 19 mg/5 mL ephedrine base) Premixed formulation –Do not dilute For Intravenous Use Only 5 mL Single-dose Prefilled Syringe Principal Display Panel – 25 mg/5 mL Vial Label
Overview
EMERPHED / EMERPHED-PFS (ephedrine sulfate injection) is a clear, colorless, sterile solution for intravenous injection. The chemical name of ephedrine sulfate is benzenemethanol, α-[1-(methylamino)ethyl]-, [ R- ( R*,S* )]-, sulfate (2:1) (salt), and the molecular weight is 428.5 g/mol. Its structural formula is depicted below: Ephedrine sulfate is freely soluble in water and ethanol, very slightly soluble in chloroform, and practically insoluble in ether. Each mL contains ephedrine sulfate, USP 5 mg (equivalent to 3.8 mg ephedrine base), 0.9% sodium chloride, USP in water for injection. The pH range is 4.5 to 7.0. Structural Formula
Indications & Usage
EMERPHED and EMERPHED-PFS is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. EMERPHED and EMERPHED-PFS is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. ( 1 )
Dosage & Administration
This is a premixed formulation. Do not dilute prior to use. Discard any unused portion of EMERPHED or EMERPHED-PFS. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. EMERPHED and EMERPHED-PFS is a clear, colorless solution. Do not use if the solution is not clear or if particulate matter is present. The single-dose prefilled syringe is intended for use in one patient during one surgical procedure. 2.1 General Dosage and Administration Instructions This is a premixed formulation. Do not dilute prior to use. Discard any unused portion of EMERPHED. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The single-dose prefilled syringe is intended for use in one patient during one surgical procedure. EMERPHED is a clear, colorless solution. Do not use if the solution is not clear or if particulate matter is present. 2.2 Dosing for the Treatment of Clinically Important Hypotension in the Setting of Anesthesia The recommended dosages for the treatment of clinically important hypotension in the setting of anesthesia is an initial dose of 5 mg to 10 mg administered by intravenous bolus. Administer additional boluses as needed, not to exceed a total dosage of 50 mg. Adjust dosage according to the blood pressure goal (i.e., titrate to effect). 2.3 Instructions for Use of Prefilled Syringe The proper method of administration of EMERPHED-PFS injection is described in the following instructions. For each single-dose prefilled syringe: Remove syringe from tray and check that it is not damaged or leaking. Inspect drug product in glass syringe for any visible particulate matter or discoloration prior to use. Discard if particulate matter or discoloration is present. Do not remove the tamper evident seal. Push plunger rod slightly in to break the stopper loose while tip cap is still on. Hold the syringe upright on the syringe barrel (C). With the other hand, take hold of the cap (A) and twist off cap counterclockwise from syringe tip (see Figure 1). Once cap (A) is off, DO NOT TOUCH THE STERILE SYRINGE TIP (Luer-Lok) (B) (see Figure 2). Discard the tip cap. Expel air bubble. Adjust dose into sterile material (if applicable). Connect the syringe to an appropriate intravenous connection. Before injection, ensure that the syringe is securely attached to the needle or needleless luer access device (NLAD). Depress plunger rod to deliver medication. Ensure that pressure is maintained on the plunger rod during the entire administration. Remove syringe from NLAD (if applicable) and discard into appropriate receptacle. To prevent needle stick injuries, do not recap needle when needle is connected to syringe. NOTE : All steps must be done sequentially Do not re-sterilize syringe Do not use this product on a sterile field Do not introduce any other fluid into the syringe at any time This product is for single dose only Figure 1 Figure 2
Warnings & Precautions
Pressor Effects with Concomitant Use with Oxytocic Drugs: Pressor effect of sympathomimetic pressor amines is potentiated ( 5.1 ) Tachyphylaxis and Tolerance: Repeated administration of EMERPHED and EMERPHED-PFS may cause tachyphylaxis ( 5.2 ) 5.1 Pressor Effect with Concomitant Oxytocic Drugs Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine) [ see Drug Interactions ( 7 ) ]. Some of these patients experienced a stroke. Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and an oxytocic. 5.2 Tolerance and Tachyphylaxis Data indicate that repeated administration of ephedrine can result in tachyphylaxis. Be aware of this possibility when treating anesthesia-induced hypotension with EMERPHED and EMERPHED-PFS and be prepared with an alternative pressor to mitigate unacceptable responsiveness. 5.3 Risk of Hypertension When Used Prophylactically When used to prevent hypotension, ephedrine has been associated with an increased incidence of hypertension compared with when ephedrine is used to treat hypotension.
Contraindications
None None ( 4 )
Adverse Reactions
The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Gastrointestinal disorders: Nausea, vomiting Cardiac disorders: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability Nervous system disorders: Dizziness Psychiatric disorders: Restlessness Most common adverse reactions during treatment : nausea, vomiting, and tachycardia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Drug Interactions
Interactions that Augment the Pressor Effect Oxytocin and oxytocic drugs Clinical Impact: Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine). Some of these patients experienced a stroke. Intervention: Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and an oxytocic. Clonidine, propofol, monoamine oxidase inhibitors (MAOIs ), atropine Clinical Impact: These drugs augment the pressor effect of ephedrine. Intervention: Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and any of these drugs. Drugs that Antagonize the Pressor Effect α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Clinical Impact: These drugs antagonize the pressor effect of ephedrine. Intervention: Carefully monitor the blood pressure of individuals who have received both EMERPHED and EMERPHED-PFS and any of these drugs. Other Drug Interactions Guanethidine Clinical Impact: EMERPHED and EMERPHED-PFS may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Intervention: Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly. Rocuronium Clinical Impact: EMERPHED and EMERPHED-PFS may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Intervention: Be aware of this potential interaction. No treatment or other interventions are needed. Epidural anesthesia Clinical Impact: EMERPHED and EMERPHED-PFS may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Intervention: Monitor and treat the patient according to clinical practice. Theophylline Clinical Impact: Concomitant use of EMERPHED and EMERPHED-PFS may increase the frequency of nausea, nervousness, and insomnia. Intervention: Monitor patient for worsening symptoms and manage symptoms according to clinical practice. Cardiac glycosides Clinical Impact: Giving EMERPHED and EMERPHED-PFS with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Intervention: Carefully monitor patients on cardiac glycosides who are also administered ephedrine. Interactions that Augment Pressor Effect: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure. ( 7 ) Interactions that Antagonize the Pressor Effect: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure. ( 7 ) Guanethidine: EMERPHED and EMERPHED-PFS may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly. Rocuronium: EMERPHED and EMERPHED-PFS may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed. Epidural anesthesia: EMERPHED and EMERPHED-PFS may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice. Theophylline: Concomitant use of EMERPHED and EMERPHED-PFS may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice. Cardiac glycosides: Giving EMERPHED and EMERPHED-PFS with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered EMERPHED and EMERPHED-PFS.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.